| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
7-Methylguanosine targets the mRNA cap structure and PARP-1. As a component of the 5' cap of eukaryotic mRNAs, it is recognized by cap-binding proteins that are essential for translation initiation. The m7G cap protects mRNA from exonucleolytic degradation and mediates nuclear export. As an inhibitor of PARP-1, the compound competes with the substrate NAD+ and binds in the PARP-1 active site. |
|---|---|
| ln Vitro |
7-Methylguanosine demonstrates in vitro activity as a component of the mRNA cap structure that is essential for translation. It is involved in protecting mRNA from degradation due to ribonucleases. As a PARP-1 inhibitor, it competes with NAD+ for binding to the enzyme's active site. The compound's activity is typically assessed in in vitro translation assays or PARP-1 inhibition assays.
|
| ln Vivo |
In vivo, 7-methylguanosine modification actively participates in many biological processes such as cell proliferation, differentiation, and apoptosis by influencing the metabolism of various RNA molecules including mRNA, rRNA, microRNA, and tRNA. The m7G modification modulates RNA secondary structure, prevents RNA degradation from exonucleases, and improves codon-dependent translation.
|
| Enzyme Assay |
In vitro enzyme assays for 7-methylguanosine involve measuring its inhibition of PARP-1 activity. The assay typically uses purified PARP-1 enzyme and measures the incorporation of NAD+ into poly(ADP-ribose) chains in the presence of the compound. The compound's role in cap-dependent translation can be assessed using in vitro translation systems.
|
| Cell Assay |
In vitro cellular assays for 7-methylguanosine are not typically performed, as it is a modified nucleoside that is naturally present in cells. Its effects on translation can be studied in cell-free translation systems or by analyzing mRNA stability and translation efficiency in cells.
|
| Animal Protocol |
In vivo animal experiments for 7-methylguanosine are not typically performed, as it is a naturally occurring modified nucleoside. Its role in RNA metabolism can be studied in various model organisms by analyzing the effects of perturbations in m7G methylation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 7-methylguanosine are limited. The compound has a molecular weight of 297.27 and a molecular formula of C11H15N5O5. It is soluble in water and should be stored under appropriate conditions. Its absorption, distribution, metabolism, and excretion properties are characteristic of nucleosides.
|
| Toxicity/Toxicokinetics |
7-Methylguanosine is a naturally occurring modified nucleoside and is not considered toxic at physiological concentrations. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
7-Methylguanosine is a positively charged methylguanosine with a methyl substituent at the 7-position. It is a metabolite belonging to the methylguanosine and organic cation classes.
7-Methylguanosine (CAS#: 20244-86-4) has the molecular formula C11H15N5O5 and a molecular weight of 297.27. It is a modified nucleoside involved in the processing of cap-dependent translational processes of mRNA. The m7G cap protects mRNA from degradation and mediates nuclear export. It is also an inhibitor of PARP-1. |
| Molecular Formula |
C11H15N5O5
|
|---|---|
| Molecular Weight |
297.27
|
| Exact Mass |
298.115
|
| CAS # |
20244-86-4
|
| Related CAS # |
7-Methylguanosine-d3
|
| PubChem CID |
135445750
|
| Appearance |
White to light yellow solid powder
|
| Melting Point |
165ºC
|
| Index of Refraction |
1.86
|
| LogP |
-1.8
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
474
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CN1C=[N+](C2=C1C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
|
| InChi Key |
OGHAROSJZRTIOK-KQYNXXCUSA-O
|
| InChi Code |
InChI=1S/C11H15N5O5/c1-15-3-16(8-5(15)9(20)14-11(12)13-8)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2-,12,13,14,20)/p+1/t4-,6-,7-,10-/m1/s1
|
| Chemical Name |
2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-methyl-1H-purin-9-ium-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 25 mg/mL (84.10 mM)
DMSO : 12.5 mg/mL (42.05 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 8.33 mg/mL (28.02 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3639 mL | 16.8197 mL | 33.6395 mL | |
| 5 mM | 0.6728 mL | 3.3639 mL | 6.7279 mL | |
| 10 mM | 0.3364 mL | 1.6820 mL | 3.3639 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
